Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota.

Lyu Y, Zhang Y, Yang M, Lin L, Yang X, Cheung SCK, Shaw PC, Chan PKS, Kong APS, Zuo Z.

Life Sci. 2019 Oct 15;235:116818. doi: 10.1016/j.lfs.2019.116818. Epub 2019 Aug 29.

PMID:
31473193
2.

Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles.

Xue M, Yang MX, Zhang W, Li XM, Gao DH, Ou ZM, Li ZP, Liu SH, Li XJ, Yang SY.

Int J Nanomedicine. 2013;8:4677-87. doi: 10.2147/IJN.S51262. Epub 2013 Dec 5.

3.

Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function.

Shan YQ, Zhu YP, Pang J, Wang YX, Song DQ, Kong WJ, Jiang JD.

Biol Pharm Bull. 2013;36(10):1562-9. Epub 2013 Aug 8.

4.

Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.

Shi R, Xu Z, Xu X, Jin J, Zhao Y, Wang T, Li Y, Ma Y.

Eur J Pharm Sci. 2019 Jan 15;127:282-290. doi: 10.1016/j.ejps.2018.11.010. Epub 2018 Nov 11.

PMID:
30428337
5.

Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism.

Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, Feng R, Ma C, Wen BY, Guo F, Yang XY, Han YX, Wang LL, Tong Q, You XF, Lin Y, Kong WJ, Si SY, Jiang JD.

Metabolism. 2017 May;70:72-84. doi: 10.1016/j.metabol.2017.02.003. Epub 2017 Feb 10.

PMID:
28403947
6.

Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux.

Shan YQ, Ren G, Wang YX, Pang J, Zhao ZY, Yao J, You XF, Si SY, Song DQ, Kong WJ, Jiang JD.

Metabolism. 2013 Mar;62(3):446-56. doi: 10.1016/j.metabol.2012.09.009. Epub 2012 Oct 15.

PMID:
23079743
7.

The involvement of multidrug and toxin extrusion protein 1 in the distribution and excretion of berberine.

Xiao L, Xue Y, Zhang C, Wang L, Lin Y, Pan G.

Xenobiotica. 2018 Mar;48(3):314-323. doi: 10.1080/00498254.2017.1300707. Epub 2017 Mar 16.

PMID:
28298174
8.

Transforming berberine into its intestine-absorbable form by the gut microbiota.

Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, Fu J, Tan XS, Li XY, Wen BY, Chen X, Yang XY, Ren G, Lin Y, Chen Y, You XF, Wang Y, Jiang JD.

Sci Rep. 2015 Jul 15;5:12155. doi: 10.1038/srep12155.

9.

Tissue distribution of berberine and its metabolites after oral administration in rats.

Tan XS, Ma JY, Feng R, Ma C, Chen WJ, Sun YP, Fu J, Huang M, He CY, Shou JW, He WY, Wang Y, Jiang JD.

PLoS One. 2013 Oct 31;8(10):e77969. doi: 10.1371/journal.pone.0077969. eCollection 2013.

10.

Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects.

Li G, Zhao M, Qiu F, Sun Y, Zhao L.

Drug Des Devel Ther. 2018 Dec 20;13:129-139. doi: 10.2147/DDDT.S185487. eCollection 2019.

11.

Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism.

Li H, Liu L, Xie L, Gan D, Jiang X.

Pharm Biol. 2016 Dec;54(12):2886-2894. Epub 2016 Jun 21.

PMID:
27327872
12.

Drug-drug interactions between ketoconazole and berberine in rats: pharmacokinetic effects benefit pharmacodynamic synergism.

Zhou Y, He P, Liu A, Zhang L, Liu Y, Dai R.

Phytother Res. 2012 May;26(5):772-7. doi: 10.1002/ptr.3621. Epub 2011 Nov 24.

PMID:
22114028
13.

Improvement of intestinal transport, absorption and anti-diabetic efficacy of berberine by using Gelucire44/14: In vitro, in situ and in vivo studies.

Sun J, Bao H, Peng Y, Zhang H, Sun Y, Qi J, Zhang H, Gao Y.

Int J Pharm. 2018 Jun 10;544(1):46-54. doi: 10.1016/j.ijpharm.2018.04.014. Epub 2018 Apr 11.

PMID:
29654898
14.

Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine.

Buchanan B, Meng Q, Poulin MM, Zuccolo J, Azike CG, Gabriele J, Baranowski DC.

PLoS One. 2018 Mar 26;13(3):e0194979. doi: 10.1371/journal.pone.0194979. eCollection 2018.

16.

Pharmacokinetic studies of novel berberine derivatives with ultra-performance liquid chromatography-tandem mass spectrometry.

Wang W, Shen Q, Liang H, Hua C, Liu Y, Li F, Li Q.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Sep 15;1031:172-180. doi: 10.1016/j.jchromb.2016.07.038. Epub 2016 Jul 18.

PMID:
27494281
17.

Comparative pharmacokinetics of active alkaloids after oral administration of Rhizoma Coptidis extract and Wuji Wan formulas in rat using a UPLC-MS/MS method.

Chen Y, Li Y, Wang Y, Yang Q, Dong Y, Weng X, Zhu X, Wang Y, Gong Z, Zhang R.

Eur J Drug Metab Pharmacokinet. 2015 Mar;40(1):67-74. doi: 10.1007/s13318-014-0181-1. Epub 2014 Mar 1.

PMID:
24577954
18.

Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid.

Godugu C, Patel AR, Doddapaneni R, Somagoni J, Singh M.

PLoS One. 2014 Mar 10;9(3):e89919. doi: 10.1371/journal.pone.0089919. eCollection 2014.

19.

Research progress on berberine with a special focus on its oral bioavailability.

Liu CS, Zheng YR, Zhang YF, Long XY.

Fitoterapia. 2016 Mar;109:274-82. doi: 10.1016/j.fitote.2016.02.001. Epub 2016 Feb 2. Review.

PMID:
26851175
20.

Enhanced Anti-diabetic Effect of Berberine Combined With Timosaponin B2 in Goto-Kakizaki Rats, Associated With Increased Variety and Exposure of Effective Substances Through Intestinal Absorption.

Tian X, Liu F, Li Z, Lin Y, Liu H, Hu P, Chen M, Sun Z, Xu Z, Zhang Y, Han L, Zhang Y, Pan G, Huang C.

Front Pharmacol. 2019 Jan 24;10:19. doi: 10.3389/fphar.2019.00019. eCollection 2019.

Supplemental Content

Support Center